Nutriband Inc. (NASDAQ: NTRB) has achieved a significant milestone by being added to four Russell indexes as part of the 2025 reconstitution. The company is now part of the Russell Microcap, Russell Microcap Growth, Russell 3000E, and Russell 3000E Growth Indexes. This inclusion is a testament to the market’s recognition of Nutriband’s growth and the potential of its AVERSA pipeline, particularly AVERSA Fentanyl, which is projected to have peak annual U.S. sales between $80 million and $200 million.

The Russell indexes, maintained by FTSE Russell, serve as benchmarks for approximately $10.6 trillion in assets and are widely utilized by investment managers and institutional investors. Nutriband’s CEO, Gareth Sheridan, emphasized that this inclusion reflects the momentum behind the company’s innovative AVERSA technology. This technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, marking a significant advancement in transdermal pharmaceutical products.

Nutriband’s lead product under development is an abuse-deterrent fentanyl patch that incorporates the AVERSA technology. The company’s focus on developing transdermal pharmaceutical products that address critical issues in drug abuse and safety underscores the importance of its work. The recognition by the Russell indexes not only validates Nutriband’s progress but also positions it for increased visibility among investors and institutions tracking these benchmarks.

For more details on Nutriband’s inclusion in the Russell indexes, visit https://ibn.fm/wa35e. This development is a clear indicator of Nutriband’s growing influence in the pharmaceutical sector and its potential to make a substantial impact with its AVERSA technology.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Nutriband Inc. Added to Four Russell Indexes in 2025 Reconstitution.